文献速递中枢神经肿瘤放疗放疗物理与技术

CT影像组学解析胶质母细胞瘤表型

Deciphering the glioblastoma phenotype by computed tomography radiomics.
PubMed 文献 · Radiother Oncol · 2021-05-10

研究纳入三个中心的218例活检确诊胶质母细胞瘤患者,基于治疗前CT图像构建临床预后评分、体积评分、复杂影像组学评分及临床联合影像组学模型,用于预测总生存;各模型交叉验证c-index为中等区分度,联合模型为0.59–0.71,与既往基于MRI的模型相当。

要点

  • CT影像组学联合临床模型可对GBM患者进行低、中、高危分层。
  • 各预后评分交叉验证c-index均为中等区分度,联合模型为0.59–0.71。
  • 该CT联合模型区分度与既往基于MRI的模型相当。

核心结论

  • 临床与CT影像组学特征可用于预测胶质母细胞瘤患者的总生存,联合模型对低、中、高危患者的区分度与既往基于MRI的模型相当。

研究设计与样本

  • 多中心回顾性研究,纳入2004至2015年在三家独立机构接受放疗±替莫唑胺治疗的218例活检确诊胶质母细胞瘤患者(各中心分别为93、62和63例)。
  • 获取临床数据与治疗前CT图像,构建临床预后评分(CPS)、基于体积的简单影像组学评分(VPS)、复杂影像组学预后评分(RPS)及临床联合影像组学评分(C+R)PS。
  • 按每种预后评分将人群分为三个风险组,并生成相应的Kaplan-Meier曲线。

主要发现

  • 患者特征总体可比,但各数据集在放疗剂量、肿瘤体积和体能状态方面存在临床显著差异。
  • 各机构间图像采集参数不同。
  • 交叉验证c-index:CPS为0.63–0.65,VPS为0.52–0.61,RPS为0.57–0.64,联合临床与影像组学模型为0.59–0.71。

关键数值与推荐

  • CPS交叉验证c-index范围为0.63–0.65。
  • VPS交叉验证c-index范围为0.52–0.61。
  • RPS交叉验证c-index范围为0.57–0.64。
  • 临床联合影像组学模型交叉验证c-index范围为0.59–0.71。

临床怎么用

  • 治疗前CT影像组学联合临床评分或可用于GBM患者总生存的风险分层,但区分度仅为中等,尚需外部验证。
  • 由于各机构图像采集参数不同且数据集间放疗剂量、肿瘤体积和体能状态存在差异,跨中心应用时需谨慎。
  • 联合模型的区分度与既往MRI模型相当,提示CT影像组学可作为MRI之外的表型信息来源。

局限性

  • 各机构间图像采集参数不一致。
  • 各数据集在放疗剂量、肿瘤体积和体能状态方面存在临床显著差异。
  • 各预后评分交叉验证c-index仅为中等区分度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumour which has, despite extensive treatment, a median overall survival of 15 months. Radiomics is the high-throughput extraction of large amounts of image features from radiographic images, which allows capturing the tumour phenotype in 3D and in a non-invasive way. In this study we assess the prognostic value of CT radiomics for overall survival in patients with a GBM. MATERIALS AND METHODS: Clinical data and pre-treatment CT images were obtained from 218 patients diagnosed with a GBM via biopsy who underwent radiotherapy +/- temozolomide between 2004 and 2015 treated at three independent institutes (n = 93, 62 and 63). A clinical prognostic score (CPS), a simple radiomics model consisting of volume based score (VPS), a complex radiomics prognostic score (RPS) and a combined clinical and radiomics (C + R)PS model were developed. The population was divided into three risk groups for each prognostic score and respective Kaplan-Meier curves were generated. RESULTS: Patient characteristics were broadly comparable. Clinically significant differences were observed with regards to radiation dose, tumour volume and performance status between datasets. Image acquisition parameters differed between institutes. The cross-validated c-indices were moderately discriminative and for the CPS ranged from 0.63 to 0.65; the VPS c-indices ranged between 0.52 and 0.61; the RPS c-indices ranged from 0.57 to 0.64 and the combined clinical and radiomics model resulted in c-indices of 0.59-0.71. CONCLUSION: In this study clinical and CT radiomics features were used to predict OS in GBM. Discrimination between low-, middle- and high-risk patients based on the combined clinical and radiomics model was comparable to previous MRI-based models.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Compter I, Verduin M, Shi Z, et al. Deciphering the glioblastoma phenotype by computed tomography radiomics. Radiother Oncol. 2021. PMID: 33984349. doi:10.1016/j.radonc.2021.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。